search
Back to results

Expanded Access to Nivolumab (Opdivo)

Primary Purpose

Pediatric Cancer

Status
Approved for marketing
Phase
Locations
Study Type
Expanded Access
Intervention
Nivolumab
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Pediatric Cancer

Eligibility Criteria

undefined - 17 Years (Child)All Sexes

Specific eligibility criteria must be met for access outside of a clinical trial.

These inclusion criteria include:

  • The illness must be serious or life threatening
  • There are no other viable options (including approved products or active clinical trials)
  • There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time
  • Other defined inclusion/exclusion criteria could be applicable.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Secondary Outcome Measures

    Full Information

    First Posted
    April 18, 2017
    Last Updated
    November 17, 2021
    Sponsor
    Bristol-Myers Squibb
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03126643
    Brief Title
    Expanded Access to Nivolumab (Opdivo)
    Official Title
    Expanded Access to Nivolumab (Opdivo)
    Study Type
    Expanded Access

    2. Study Status

    Record Verification Date
    November 2021
    Overall Recruitment Status
    Approved for marketing
    Study Start Date
    undefined (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Bristol-Myers Squibb

    4. Oversight

    5. Study Description

    Brief Summary
    At BMS, we work with physicians/investigators to make investigational products available to patients with life-threatening diseases that have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. When contacted by a treating physician, BMS will consider requests for providing early patient access to Nivolumab in pediatric patients exhibiting a high mutational load.
    Detailed Description
    Choosing to participate in an early patient access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join an early patient access program. To learn more about early patient access programs, your doctor may contact BMS using the information provided below.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pediatric Cancer

    7. Study Design

    8. Arms, Groups, and Interventions

    Intervention Type
    Biological
    Intervention Name(s)
    Nivolumab
    Other Intervention Name(s)
    Opdivo, BMS-936558
    Intervention Description
    Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an "accelerated" basis for some types of cancer. Please contact your physician for more details.

    10. Eligibility

    Sex
    All
    Maximum Age & Unit of Time
    17 Years
    Eligibility Criteria
    Specific eligibility criteria must be met for access outside of a clinical trial. These inclusion criteria include: The illness must be serious or life threatening There are no other viable options (including approved products or active clinical trials) There is sufficient evidence that the potential benefit to the patient would likely outweigh the potential risks based on what is known at the time Other defined inclusion/exclusion criteria could be applicable.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Bristol-Myers Squibb
    Organizational Affiliation
    Bristol-Myers Squibb
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Links:
    URL
    https://www.bms.com/healthcare-providers/early-patient-access-to-investigational-medicine.html
    Description
    Information for Early Patient Access to Investigational Drugs

    Learn more about this trial

    Expanded Access to Nivolumab (Opdivo)

    We'll reach out to this number within 24 hrs